Supernus Pharmaceuticals, Inc. (SUPN) presented data on both its epilepsy drugs – Trokendi XR and Oxtellar XR, at the American Epilepsy Society (AES) meeting.
Supernus launched its antiepileptic drug, Oxtellar XR, in the U.S in Feb 2013. During the double-blind PROSPER study on Oxtellar XR, seizure control was maintained. In addition, seizure control further improved during the long term open-label extension when dosages could be optimized. Further, Oxtellar XR was very well tolerated during long-term maintenance therapy.
Growth in the Oxtellar XR prescriber base has been phenomenal in the third quarter of 2013, totaling 7,596, up from 3,648 in the second quarter. Since its launch, more than 1,600 target physicians have prescribed Oxtellar XR.
Supernus launched Trokendi XR in the third quarter of 2013. 93% of patients preferred Trokendi XR when switched from twice daily immediate release Topamax. Likewise, 92% of epileptic patients expect Trokendi XR to deliver better results. Trokendi XR (once daily) was revealed as bioequivalent to Topamax (twice) in a head to head study.
With Trokendi XR there is a convenience of taking a dose of Topamax (once) without increasing the risks of missed, delayed, or doubled doses. In elder patients, dosage recommendations for Trokendi XR are similar to that of immediate release Topamax.
By Nov 1, 2013, 4,711 prescriptions were reported by IMS for Trokendi XR. To aid the launch of Trokendi XR, Supernus increased its sales force by 15 sales representatives. Additional sales force expansion is expected shortly.
Trokendi XR and Oxtellar XR are the only marketed products at Supernus. This additional data on the drugs was encouraging.
Supenus currently carries a Zacks Rank #2 (Buy). Some better-ranked stocks include Aeterna Zentaris Inc. (AEZS), Actelion Ltd. (ALIOF) and Jazz Pharmaceuticals plc (JAZZ), each carrying a Zacks Rank #1 (Strong Buy).
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment